A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer

To investigate the long-term safety of the dose regimen of degarelix proposed for marketing in patients with prostate cancer.